These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 28666686)

  • 1. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
    Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
    Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma.
    Huebner M; Kendrick M; Reid-Lombardo KM; Que F; Therneau T; Qin R; Donohue J; Nagorney D; Farnell M; Sarr M
    J Gastrointest Surg; 2012 May; 16(5):920-6. PubMed ID: 22421988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head.
    Prenzel KL; Hölscher AH; Vallböhmer D; Drebber U; Gutschow CA; Mönig SP; Stippel DL
    Eur J Surg Oncol; 2010 Oct; 36(10):993-6. PubMed ID: 20594789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma.
    Ashfaq A; Pockaj BA; Gray RJ; Halfdanarson TR; Wasif N
    J Gastrointest Surg; 2014 Nov; 18(11):1929-35. PubMed ID: 24916590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.
    Sada YH; Smaglo BG; Tan JC; Tran Cao HS; Musher BL; Massarweh NN
    J Natl Compr Canc Netw; 2019 Feb; 17(2):161-168. PubMed ID: 30787129
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.
    Honselmann KC; Pergolini I; Castillo CF; Deshpande V; Ting D; Taylor MS; Bolm L; Qadan M; Wellner U; Sandini M; Bausch D; Warshaw AL; Lillemoe KD; Keck T; Ferrone CR
    Ann Surg; 2020 Aug; 272(2):357-365. PubMed ID: 32675550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 18. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing.
    Oppliger FA; Prakash LR; Newhook TE; Chiang YJ; Ikoma N; Maxwell JE; Kim MP; Vauthey JN; Lee JE; Katz MH; Tzeng CD
    Surg Oncol; 2022 Mar; 40():101673. PubMed ID: 34894620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer.
    Eskander MF; de Geus SW; Kasumova GG; Ng SC; Al-Refaie W; Ayata G; Tseng JF
    Surgery; 2017 Apr; 161(4):968-976. PubMed ID: 27865602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.